RESEARCH

BMC Cancer





Receipt of mastectomy and adjuvant radiotherapy following breast conserving surgery (BCS) in New Zealand women with BCS-eligible breast cancer, 2010–2015: an observational study focusing on ethnic differences

Karen Bartholomew^{1,2}, Mazin Ghafel^{1,2}, Sandar Tin Tin³, Phyu S Aye^{1,3*}, J Mark Elwood³, Claire Hardie⁴, Nina Scott⁵, Jacquie Kidd⁶, Reena Ramsaroop¹ and Ian Campbell⁵

Abstract

Background Women with early breast cancer who meet guideline-based criteria should be offered breast conserving surgery (BCS) with adjuvant radiotherapy as an alternative to mastectomy. New Zealand (NZ) has documented ethnic disparities in screening access and in breast cancer treatment pathways. This study aimed to determine whether, among BCS-eligible women, rates of receipt of mastectomy or radiotherapy differed by ethnicity and other factors.

Methods The study assessed management of women with early breast cancer (ductal carcinoma in situ [DCIS] and invasive stages I-IIIA) registered between 2010 and 2015, extracted from the recently consolidated New Zealand Breast Cancer Registry (now Te Rēhita Mate Ūtaetae NZBCF National Breast Cancer Register). Specific criteria were applied to determine women eligible for BCS. Uni- and multivariable analyses were undertaken to examine differences by demographic and clinicopathological factors with a primary focus on ethnicity (Māori, Pacific, Asian, and Other; the latter is defined as NZ European, Other European, and Middle Eastern Latin American and African).

Results Overall 22.2% of 5520 BCS-eligible women were treated with mastectomy, and 91.1% of 3807 women who undertook BCS received adjuvant radiotherapy (93.5% for invasive cancer, and 78.3% for DCIS). Asian ethnicity was associated with a higher mastectomy rate in the invasive cancer group (OR 2.18; 95%CI 1.72–2.75), compared to Other ethnicity, along with older age, symptomatic diagnosis, advanced stage, larger tumour, HER2-positive, and hormone receptor-negative groups. Pacific ethnicity was associated with a lower adjuvant radiotherapy rate, compared to Other ethnicity, in both invasive and DCIS groups, along with older age, symptomatic diagnosis, and lower grade

*Correspondence: Phyu S Aye p.aye@auckland.ac.nz

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

tumour in the invasive group. Both mastectomy and adjuvant radiotherapy rates decreased over time. For those who did not receive radiotherapy, non-referral by a clinician was the most common documented reason (8%), followed by patient decline after being referred (5%).

Conclusion Rates of radiotherapy use are high by international standards. Further research is required to understand differences by ethnicity in both rates of mastectomy and lower rates of radiotherapy after BCS for Pacific women, and the reasons for non-referral by clinicians.

Keywords Breast cancer, Breast conserving surgery, Mastectomy, Adjuvant radiotherapy, Ethnicity, New Zealand

Background

Breast cancer is the most common cancer and the second leading cause of death for New Zealand women [1]. Breast cancer incidence and outcomes differ substantially by ethnicity. Māori and Pacific women had a higher incidence of breast cancer than New Zealand European women, but were less likely to be diagnosed via screening mammography, and therefore were frequently diagnosed at a more advanced stage [2–4]. Mortality from breast cancer in indigenous Māori and Pacific women is nearly double that of women of other ethnicities [5].

The standard treatment in New Zealand, according to the 2009 Guidelines for Early Breast Cancer Management [6], is the choice of breast conserving surgery (BCS) or mastectomy to all women who are eligible for BCS. BCS improves psychological (for women who wish to have breast conservation) and cosmetic outcomes [7] and when followed by adjuvant radiotherapy has demonstrated superior survival outcomes compared to mastectomy alone in observational studies [8–11]. Standard adjuvant radiotherapy usually involves a course of whole breast external-beam radiotherapy with or without a boost to the surgical tumour bed delivered daily over a number of weeks [6, 12]. Among women with node-negative disease, adjuvant radiotherapy reduces the 10-year risk of a first local recurrence of breast cancer by 15.4% and the 15-year risk of breast cancer-related mortality by 3.3% [13]. However, the duration of standard adjuvant radiotherapy may lead women to choose mastectomy rather than BCS [14].

Previous New Zealand research by colleagues using data from the Auckland and Waikato regional Breast Cancer Registers indicated that Māori and Pacific women with early breast cancer were significantly more likely to receive mastectomy [5, 15, 16], more likely to have treatment delays [5, 17], and less likely to receive radiotherapy after BCS than other women [5]. According to international studies, receipt of adjuvant radiotherapy for early stage breast cancer differed by socioeconomic status, ethnicity, age and travel distance for treatment [18, 19].

To better understand how ethnicity and other demographic and clinical factors influenced treatment choices in New Zealand women with breast cancer, this study used the data from the New Zealand Breast Cancer Register (NZBCR) and investigated (1) receipt of mastectomy in women with early breast cancer who were eligible for BCS, and (2) receipt of adjuvant radiotherapy in women who received BCS as their final surgery.

Methods

Data sources

This study is a population-based cross-sectional observational study, using the data of women with newly diagnosed early breast cancer, extracted from the New Zealand Breast Cancer Register (NZBCR) for the period of 2000–2015. The NZBCR is now a national nationwide database – from 2020. At the time of data extraction, the NZBCR had been prospectively consolidated data from four population-based opt-out registries in four areas: Auckland, Waikato, Wellington, and Christchurch. These registries represented data of nearly complete population-based series, accounted for approximately 67% of newly diagnosed breast cancers in New Zealand, with an opt-out rates of 1.6% in 2003–2012, and 0.1% in 2012–2020 [3]. The use of opt-out consent systems enhance reporting unbiased results [20].

Study population

The study included all women with early breast cancer who were eligible for breast conserving surgery (BCS). Early breast cancer comprised of invasive breast cancer (stages I-IIIA) and ductal carcinoma in situ (DCIS). To be eligible for BCS, the following were excluded: unknown tumour size or a tumour size of \geq 30 mm, no breast surgery, multifocal ipsilateral breast cancer, unknown invasive or in situ, stage IIIB-IV or unknown stage, lobular carcinoma in situ alone, being pregnant at the time of diagnosis, and male, transgender or unknown gender [21]. The study period was restricted to 2010–2015, for which the complete data was available across all four geographical regions.

Variables

Ethnicity was the primary variable of interest, sourced from contributing hospital records and associated with the National Health Index (NHI) number. Guidance and requirements for the collection, recording and output of ethnicity data in New Zealand is covered in the Health and Disability Sector Ethnicity Data Standards [22]. In New Zealand ethnicity is self-identified using the standardised ethnicity question, and patients are able to identify multiple ethnic groups. For women who identified multiple ethnicities, the ethnicity used in this analysis was prioritised in the order Māori>Pacific>Asian>Othe r, allowing one assigned ethnicity per patient. The 'Other ethnicity' category is the largest and included women identifying as NZ European, Other European, and Middle Eastern Latin American and African (MELAA). In the source dataset only 12 (0.2%) of ethnicity data was missing. We acknowledge that there are known issues with ethnicity data quality using any routine dataset, including NHI ethnicity [23].

Demographic variables of interest included age at diagnosis, and measures of rurality and deprivation status. Rurality was categorised as rural or urban, according to Statistics NZ definitions based on patients' residential address [24]. Deprivation status, which reflects individuals' socioeconomic status, was calculated using NZ Deprivation (2013) decile scores [25], and categorised into quintiles 1–5 (1=least deprived, 5=most deprived).

Clinical variables included mode of diagnosis (whether detected by mammographic screening or symptoms), diagnosis year, type of healthcare facility (public or private), the histopathological stage of the primary tumour (stages I-IIIA, DCIS), hormone status of tumour (presence of oestrogen and/or progesterone receptors), HER2 status, histological grade (1-3), lesion size, presence of lymphovascular invasion and the patient's menopausal status. We used histopathological stage because while clinical staging contributes to initial surgeon decision making around breast conservation, histopathology results ultimately determine whether initial breast conservation needs to be converted to mastectomy, and the need for radiotherapy in many cases. Histopathology also provides more accurate information on tumour stage and patient prognosis [26]. The stages (I-IIIA) were classified based on the tumour size and lymph node involvement, referencing the American Society of Clinical Oncology Breast Cancer Staging [26]. This classification of stage is presented in supplementary Table 1.

The primary outcome variables were receipt of mastectomy, and receipt of radiotherapy for women who underwent BCS. The following were included as BCS: lumpectomy and any form of excision biopsy (where no subsequent excision was undertaken), wide local excision, partial mastectomy, and re-excision. The receipt of radiotherapy following BCS was recorded as a binary 'yes' or 'no' variable, as the data on courses of radiotherapy were unavailable from the NZBCR.

Those women who underwent BCS but did not receive adjuvant radiotherapy were categorised as referred or not referred for radiotherapy; each category was sub-grouped according to whether the clinician deemed not necessary, patient had declined, or patient was unfit for radiotherapy.

Statistical analysis

Descriptive analyses were performed to present the numbers and percentages of the cohort in subgroups, and the distributions by ethnicity. Univariable analyses were used to observe the associations between the outcomes and individual variables of interest and reported using crude odds ratios (ORs) with 95% confidence intervals (95%CI). Multivariable logistic regression analyses were undertaken to identify the factors independently associated with each outcome. Separate analyses were conducted for the group of women with invasive disease and those with in situ disease including all the relevant demographic and clinicopathological factors for each group, without excluding the non-significant factors to minimise residual confounding. The effects were expressed as adjusted ORs with 95% CI, with p<0.05 considered statistically significant. The analysis was undertaken using Python 3.7 statistical package.

Ethics approval

The Te Rēhita Mate Ūtaetae, New Zealand Breast Cancer Registry, maintains its own governance and New Zealand Health and Disability Ethics Committee approval, using opt-out consent [3]. The analysis of the registry data for this study was additionally approved by the Health and Disability Ethics Committees (18/STH/165), and primary site localities at Waitematā (RM#13,920). All methods were carried out in accordance with relevant guidelines and regulations.

Results

Of the total 22,864 registrations identified from the New Zealand Breast Cancer Registry (NZBCR) for 2000–2015, 10,704 women were eligible for analysis. After restricting the data to 2010–2015, the analyses included 5520 eligible women (Fig. 1). Most women (62.3%) were aged 50–69 years (Table 1). Māori women accounted for 8.2%, Pacific 4.0%, Asian 8.6% and Other ethnic group 78.7% of the cohort. Other population characteristics included invasive cancers (82.3%), a larger tumour size>20 mm (44.4%), stage I (68.4%), lower grade 1–2 (62.2%), HER2 negative (82.8%) for those with invasive disease, and hormone receptor positive (84%) for those with invasive disease. Nearly two-third (63.7%) of women were screendetected, and the majority were treated in the public health system.

Regarding subgroups by ethnicity (Table 1), Asian women had a higher proportion of in situ cancers (27.6%) compared to women of other ethnicities (14–17%). Māori women were slightly more commonly diagnosed through



Fig. 1 Flow diagram showing eligible patient selection. BCS = breast conserving surgery, RT = radiotherapy; * women with multiple lesions n=7021, men n=148, women with metastasis n=1770, pregnant women n=11, women with no surgery n=969, tumour size unknown or >30 mm n=2241

screening (69.2%), followed by Pacific women (68.6%), compared to Asian and Other ethnicity (63%).

Receipt of mastectomy in BCS eligible women

Of the 5520 BCS-eligible women, 1228 (22.2%) received mastectomy, with rates of 24.5% for women with invasive disease, and 11.8% for in situ disease (Table 2).

For the invasive group, the univariable analysis indicated that the receipt of mastectomy was about two times higher in Asian women (OR 2.18; 95% CI 1.72–2.75), with no significant differences for Māori and Pacific women when compared to women of Other ethnicity. The multivariable analysis showed similar ethnic differences. The other factors significantly associated with higher mastectomy rate included age \geq 70 years, symptomatic disease, more advanced stages (II and III), grade 2, larger size (\geq 11 mm), hormone receptor-negative, HER2-positive, and diagnosed in 2010/11 (Table 2; Fig. 2a). No difference was seen by rurality.

For the in situ group, both univariable and multivariable analyses showed no significant differences in receiving mastectomy by ethnicity or other factors, except that mastectomy was more likely to be received in women with symptomatic disease than those with screen-detected disease (OR 2.55; 95% CI 1.48–4.41) (Table 2).

	Total	Ethnicity				
	N (%)	Māori Pacific Asian 465 (9.200) 222 (4.000) 474 (9.600)		Other	Unknown	
Totals	5520	465 (8.2%)	465 (8.2%) 223 (4.0%) 474 (8.6%) 4346 (4346 (78.7%)	12 (0.2%)
Age group						
≤49 years	1192 (21.6%)	128 (27.5%)	58 (26.0%)	159 (33.5%)	847 (19.5%)	0 (0%)
50–69 years	3440 (62.3%)	310 (66.7%)	152 (68.2%)	285 (60.1%)	2681 (61.7%)	12 (100%)
70–79 years	636 (11.5%)	21 (4.5%)	11 (4.9%)	25 (5.3%)	579 (13.3%)	0 (0%)
≥80 years	252 (4.6%)	6 (1.3%)	2 (0.9%)	5 (1.1%)	239 (5.5%)	0 (0%)
Cancer type						
Invasive	4541 (82.3%)	398 (85.6%)	186 (83.4%)	343 (72.4%)	3607 (83.0%)	7 (82.3%)
In situ	979 (17.7%)	67 (14.4%)	37 (16.6%)	131 (27.6%)	739 (17.0%)	5 (17.7%)
Size						
< 10 mm	1558 (28.8%)	120 (25.8%)	58 (26%)	133 (28.1%)	1241 (28.6%)	6 (50%)
11-19 mm	1478 (26.8%)	129 (27.7%)	72 (32.3%)	134 (28.3%)	1140 (26.2%)	3 (25%)
> 20 mm	2484 (44.4%)	216 (46.5%)	93 (41.7%)	207 (43.7%)	1965 (45.2%)	3 (25%)
Stage						
	3778 (68.4%)	306 (65.8%)	139 (62.3%)	330 (69.6%)	2993 (68.9%)	10 (83.3%)
IIA	1296 (23.5%)	116 (24.9%)	60 (26.9%)	113 (23.8%)	1005 (23.1%)	2 (16.7%)
IIB	347 (6.3%)	36 (7.7%)	21 (9.4%)	25 (5.3%)	265 (6.1%)	0 (0%)
IIIA	99 (1.8%)	7 (1.5%)	3 (1.3%)	6 (1.3%)	83 (1.9%)	0 (0%)
Grade						
1	1346 (24.4%)	114 (24.5%)	45 (20.2%)	101 (21.3%)	1083 (24.9%)	3 (25%)
2	2088 (37.8%)	197 (42.4%)	94 (42.2%)	152 (32.1%)	1642 (37.8%)	3 (25%)
3	1057 (19.1%)	81 (17.4%)	44 (19.7%)	85 (17.9%)	846 (19.5%)	1 (8.3%)
Unknown	1029 (18.7%)	73 (15.7%)	40 (17.9%)	136 (28.7%)	775 (17.8%)	5 (41.7%)
HER2 status (invasive)						
Subtotal	4541	398	186	343	3607	7
Equivocal	137 (3.0%)	20 (5.0%)	4 (2.2%)	5 (1.5%)	107 (3.0%)	1 (14.3%)
Negative	3759 (82.8%)	317 (79.6%)	154 (82.8%)	287 (83.7%)	2996 (83.1%)	5 (71.4%)
Positive	438 (9.6%)	40 (10.1%)	21 (11.3%)	41 (12.0%)	335 (9.3%)	1 (14.3%)
Unknown	207 (4.6%)	21 (5.3%)	7 (3.8%)	10 (2.9%)	169 (4.7%)	0 (0.0%)
HER2 status (in situ)						
Subtotal	979	67	37	131	739	5
Equivocal	5 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.7%)	0 (0.0%)
Negative	50 (5.1%)	6 (9.0%)	1 (2.7%)	6 (4.6%)	36 (4.9%)	1 (20.0%)
Positive	11 (1.1%)	1 (1.5%)	0 (0.0%)	1 (0.8%)	9 (1.2%)	0 (0.0%)
Unknown	913 (93.3%)	60 (89.6%)	36 (97.3%)	124 (94.7%)	689 (93.2%)	4 (80.0%)
Hormone receptor (invasive))					
Subtotal	4541	398	186	343	3607	7
Both neg	491 (10.8%)	18 (4.5%)	20 (10.8%)	38 (11.1%)	415 (11.5%)	0 (0.0%)
Both pos	3025 (66.6%)	247 (62.1%)	141 (75.8%)	245 (71.4%)	2392 (66.3%)	0 (0.0%)
Pos / neg	792 (17.4%)	88 (22.1%)	18 (9.7%)	57 (16.6%)	627 (17.4%)	2 (28.6%)
Unknown	233 (5.1%)	45 (11.3%)	7 (3.8%)	3 (0.9%)	173 (4.8%)	5 (71.4%)
Hormone receptor (in situ)			()			
Subtotal	979	67	37	131	739	5
Both neg	9 (0.9%)	0 (0.0%)	1 (2.7%)	1 (0.8%)	7 (0.9%)	0 (0.0%)
Both pos	46 (4.7%)	4 (6.0%)	0 (0.0%)	5 (3.8%)	35 (4.7%)	2 (40.0%)
Pos / nea	60 (6.1%)	5 (7.5%)	1 (2.7%)	6 (4.6%)	45 (6.1%)	3 (60.0%)
Unknown	864 (88.3%)	58 (86.6%)	35 (94.6%)	119 (90.8%)	652 (88.2%)	0 (0.0%)
Mode of diagnosis				,		
Screen-detected	3518 (63.7%)	322 (69.2%)	153 (68.6%)	299 (63.1%)	2738 (63%)	6 (50%)
Symptomatic	2002 (36.3%)	143 (30.8%)	70 (31.4%)	175 (36.9%)	1608 (37%)	6 (50%)
Facility		·····	· · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·
Public	3292 (59.6%)	346 (74.4%%)	179 (80,3%)	313 (66.0%)	2447 (56.3%)	7 (58,3%)
Private	1210 (21 9%)	28 (6.0%)	8 (3.6%)	111 (23.4%)	1058 (24 3%)	5 (41.7%)
Unknown	1018 (18.4%)	91 (19.6%)	36 (16 1%)	50 (10 5%)	841 (19.4%)	0 (0%)

Table 1 Patient characteristics, showing distributions by ethnicity

Total Age-group						Ductal (arcinoma in situ:			
Total Age-group	Total	Mastectomy	Crude OR	Adjusted OR	1	Total	Mastectomy	Crude OR	Adjusted OR	
Total Age-group < 40 ware	z	n (%)	(95% CI)	(95% CI)		z	n (%)	(95% CI)	(95% CI)	
Age-group	4541	1112 (24.5)				979	116 (11.8)			
< AQ viagre										
D T J J C M J	949	235 (24.8)	1.46 (1.22–1.75)	0.96 (0.72–1.28)		243	30 (12.3)	1.38 (0.87–2.19)	0.86 (0.44–1.69)	
50-69 years	2786	539 (19.3)		, —		654	68 (10.4)		-	
70–79 years	566	208 (36.7)	2.52 (2.05–2.52)	1.73 (1.37–2.18)	***	70	14 (20.0)	2.40 (1.26–4.56)	1.72 (0.80–3.70)	
≥ 80 years	240	130 (54.2)	5.77 (4.34–7.67)	3.19 (2.31–4.42)	***	12	4 (33.3)	4.80 (1.40-16.39)	2.66 (0.65-10.82)	
Ethnicity										
Māori	398	81 (20.4)	0.72 (0.55–0.95)	0.96 (0.72–1.29)		67	8 (11.9)	1.12 (0.52–2.42)	1.23 (0.53–2.86)	
Pacific	186	51 (27.4)	1.22 (0.87–1.71)	1.12 (0.76–1.64)		37	4 (10.8)	1.00 (0.34–2.89)	0.64 (0.19–2.14)	
Asian	343	134 (39.1)	2.18 (1.72–2.75)	2.20 (1.7–2.86)	***	131	18 (13.7)	1.31 (0.76–2.27)	1.31 (0.73–2.38)	
Other	3607	844 (23.4)	-	, —		739	84 (11.4)	,		
Unknown	7	2 (28.6)		I		5	2 (40.0)	ı		
Mode of Diagnosis										
Screen-detected	2692	434 (16.1)		,		826	78 (9.4)	-	—	
Symptomatic	1849	678 (36.7)	3.00 (2.60–3.47)	1.97 (1.66–2.35)	***	153	38 (24.8)	3.07 (1.96–4.80)	2.55 (1.48-4.41)	***
Year of Diagnosis										
Year 2010/11	1425	371 (26.0)	1.18 (0.99–1.39)	<u>1.24 (1.03–1.49)</u>	*	310	41 (13.2)	1.23 (0.78–1.96)	1.06 (0.64–1.74)	
Year 2012/13	1458	356 (24.4)	1.04 (0.8 8-1.24)	1.15 (0.96–1.38)		281	31 (11.0)	0.97 (0.59–1.60)	0.87 (0.50–1.5)	
Year 2014/15	1658	385 (23.2)		,		388	44 (11.3)			
Menopausal Status										
Pre-menopausal	1133	278 (24.5)	1.30 (0.91–1.88)	0.99 (0.67–1.46)		315	43 (13.7)	1.47 (0.50–4.33)	1.26 (0.38–4.17)	
Peri-menopausal	231	46 (19.9)	-	-		44	5 (11.4)	1	1	
Post-menopausal	3177	788 (24.8)	1.34 (0.94–1.89)	0.97 (0.66–1.41)		620	68 (11.0)	1.13 (0.39–3.28)	0.91 (0.28–2.89)	
Facility Type										
Private	983	225 (22.9)	1.14 (0.90–1.29)	0.98 (0.78–1.23)		227	26 (11.5)	1.14 (0.70–1.85)	1.13 (0.6–2.14)	
Public	2704	671 (24.8)	-	-		588	65 (11.1)	-		
Unknown	854	216 (25.3)		ı		164	25 (15.2)	ı		
Stage										
_	2799	492 (17.6)	-	-						
IIA	1296	428 (33.0)	2.07 (1.77–2.44)	1.57 (1.22-2.01)	**					
IIB	347	142 (40.9)	3.45 (2.64–4.50)	1.99 (1.37–2.91)	***					
HIIA	66	50 (50.5)	3.84 (2.49–5.94)	3.72 (2.31–6.01)	***					
HER2 Status										
Equivocal	123	20 (16.3)	0.65 (0.39–1.08)	0.84 (0.48–1.45)						
Negative	3744	828 (22.1)	-	, -						
Positive	433	145 (33.5)	1.78 (1.42–2.21)	<u>1.55 (1.21–1.97)</u>	***					
Unknown	241	119 (49.4)	1	1						

. -+-777 sto Č 2 (in Ę ź oldioilo) U U U U f 2.

						המרומו רמ			
	Total	Mastectomy	Crude OR	Adjusted OR		Total	Mastectomy	Crude OR	Adjusted OR
	z	(%) u	(95% CI)	(95% CI)		Z	u (%)	(95% CI)	(95% CI)
Grade									
, —	1346	224 (16.6)	,	-					
2	2088	527 (25.2)	1.71 (1.42–2.04)	<u>1.34 (1.1–1.63)</u>	**				
c	1055	341 (32.3)	2.33 (1.90–2.85)	1.28 (0.99–1.64)					
Unknown	52	20 (38.5)	ı						
Size									
< 10 mm	1149	178 (15.5)	-	-					
11-19 mm	1265	488 (38.6)	3.82 (3.12–4.67)	<u>1.74 (1.24–2.44)</u>	**				
> 20 mm	2127	446 (21.0)	1.81 (1.51–2.17)	<u>1.29 (1.04–1.60)</u>	***				
Lymphovascular Invasion									
No	3720	869 (23.4)	,	-					
Yes	792	235 (29.7)	1.34 (1.13–1.61)	0.84 (0.69–1.03)	*				
Unknown	29	8 (27.6)	ı						
Hormone receptor									
Both negative	491	179 (36.5)	1.87 (1.51–2.31)	<u>1.5 (1.16–1.93)</u>	***				
Both positive	3025	725 (24.0)	-	-					
One pos/one neg	792	152 (19.2)	0.72 (0.59–0.89)	1.10 (0.87–1.39)					
Unknown	233	56 (24.0)	ı	ı					
Rurality									
Rural	187	30 (16.0)	0.64 (0.44–0.93)	1.03 (0.68–1.55)					
Urban	2606	630 (24.2)		-					
Unknown	1748	452 (25.9)	ı	ı					
Deprivation Status									
NZDep Quintile 1	621	140 (22.5)	-	-					
NZDep Quintile 2	745	178 (23.9)	1.15 (0.88–1.49)	1.00 (0.76–1.32)					
NZDep Quintile 3	643	148 (23.0)	1.05 (0.80-1.38)	1.16 (0.86–1.56)					
NZDep Quintile 4	558	133 (23.8)	1.05 (0.79–1.4)	1.22 (0.89–1.68)					
NZDep Quintile 5	142	35 (24.6)	1.17 (0.75–1.81)	0.98 (0.59–1.64)					
Unknown	1832	478 (26.1)	1						

Table 2 (continued)



Fig. 2 Factors significantly affecting **a**) receipt of mastectomy in women with invasive breast cancer who were eligible for breast conserving surgery (BCS); **b**) receipt of adjuvant radiotherapy following BCS in women with invasive breast cancer. Note: Based on the multivariable logistic regression model; only significant factors are shown; factors not shown in figure (**a**) are menopausal status, facility type, rurality, and deprivation status; and factors not shown in figure (**b**) are menopausal status, size, lymphovascular invasion, hormone status, rurality, and deprivation status

Receipt of adjuvant radiotherapy following BCS

Of the 3809 women who received BCS, 3468 (91%) received adjuvant radiotherapy, with rates of 93.5% for women with invasive disease, and 78.3% for in situ disease (Table 3).

For the invasive group, the univariable analysis showed that the receipt of adjuvant radiotherapy was significantly less likely in Pacific women (OR 0.47; 95% CI 0.27–0.80),

with no significant differences for Māori and Asian, compared to Other ethnicity. When adjusted for other factors, the association with Pacific ethnicity showed a larger effect (OR 0.39; 95% CI 0.21–0.72), and the association with Asian (more likely) was significant (OR 2.45; 95% CI 1.04–5.79). Adjuvant radiotherapy was also less likely to be received in women aged \geq 70 years, and in symptomatic disease. In contrast, the receipt of adjuvant

.⊆
g
Ě
ğ
Ū.
g
t
Ĕ
g
à
ē
Ĕ
g
st
Ga
S.
Ū
.≥
as
2
÷
be
Ę
5
ğ
ar
0
â
~
ē
<u>S</u>
SL
a
\subseteq
Sf
S as fi
SCS as f
t BCS as fi
ent BCS as fi
went BCS as fi
erwent BCS as fi
iderwent BCS as fi
underwent BCS as fi
o underwent BCS as fi
vho underwent BCS as fi
who underwent BCS as fi אין who underwent
en who underwent BCS as fi
men who underwent BCS as fi
vomen who underwent BCS as fi
ר women who underwent BCS as f
/ in women who underwent BCS as fi
ipy in women who underwent BCS as fi
arapy in women who underwent BCS as fi
herapy in women who underwent BCS as fi
otherapy in women who underwent BCS as fi
idiotherapy in women who underwent BCS as fi
radiotherapy in women who underwent BCS as fi
nt radiotherapy in women who underwent BCS as fi
vant radiotherapy in women who underwent BCS as fi
juvant radiotherapy in women who underwent BCS as fi
adjuvant radiotherapy in women who underwent BCS as fi
of adjuvant radiotherapy in women who underwent BCS as fi
t of adjuvant radiotherapy in women who underwent BCS as fi
ipt of adjuvant radiotherapy in women who underwent BCS as fi
ceipt of adjuvant radiotherapy in women who underwent BCS as fi
Receipt of adjuvant radiotherapy in women who underwent BCS as fi
: Receipt of adjuvant radiotherapy in women who underwent BCS as fi
3 Receipt of adjuvant radiotherapy in women who underwent BCS as fi
yle 3 Receipt of adjuvant radiotherapy in women who underwent BCS as fi
able 3 Receipt of adjuvant radiotherapy in women who underwent BCS as fi

Globoly Total Adjustmy (a) Conde (c) (a) Adjustmy(a)		-	Invasiv	e.				Ducta	l carcinoma in si	tu		
No. No. No. No. No. No. Deal 283 283633 1 1 0 47083 1 0 47083 Aberyolic 549ers 26 600501 148005-238 166.085-316 1 0 47083 0 47083 25-05yers 232 290680 0.47023-2032 0.25001-0.201 0 47083 1 1 1 27-75yers 232 290680 0.47023-303 0.25001-020 2 2 266010-021-020 0	Category		Total	Adjuvant radiotherapy	Crude OR (95% CI)	Adjusted OR (95% CI)	1	Total	Adjuvant radiotherapy	Crude OR (95% CI)	Adjusted OR (95% CI)	
Total 202 396 (9.5) 1 0 475 (3.5) 3 476 (3.1) Age prote 56 66 (9.6) 1 6(0 (6.4) 1 6(0 (6.4) 1 6(0 (6.4) 1 6(0 (6.4) 1 6(0 (6.4) 1 6(0 (6.4) 1 6(0 (6.4) 1 6(0 (6.4) 1 6(0 (6.4) 1 6(0 (6.4) 1 <			z	(%) u	1			z	(%) u			
Agendual	Total		3202	2993 (93.5)				607	475 (78.3)			
Selection Selection <t< td=""><td>Age-group</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Age-group											
50-69/sers 271 1996/4.21 1 1 2.23 3458.11 1 1 1 Ethrlefy 77-39/sers 33 607.23 0.4100-52.06 0.51 0.4703-400 0.4703-400 0.4703-400 0.4700-111 Ethrlefy 77 35 2468.06 0.4100-526 0.2100-550 25100-5272 4 23 366.01 1.570.46 1.970.04 0.4700-406 1.9700-406<		≤ 49 years	666	640 (96.1)	1.48 (0.96–2.28)	1.68 (0.89–3.16)		149	112 (75.2)	0.73 (0.47–1.15)	0.46 (0.22-0.96)	*
Tomprise 332 34 (88) 0.47 (0.32-0.69) 0.55 (0.03-2.05) 0.47 (0.03-11)		50-69 years	2121	1 999 (94.2)	1	—		423	343 (81.1)	,	-	
Endore 2.60 years 3.1 0.072.3 0.14 (0.06-0.2) 0.22 (0.01-0.02) 3.1 (3.3.3) - - - Refice 1.28 1.86 (0.01 1.56 (0.04-0.1) 1.7 (0.06-0.1) 28 3.3 (0.69 (3-4.6) 1.90 (0.54-4.6) 1.90 (0.56-4.6) 1.90 (0.56-4.6) 1.90 (0.56-4.6) 1.90 (0.56-4.6) 1.90 (0.56-4.6) 1.90 (0.56-4.6) 1.90 (0.56-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.50-4.6) 1.90 (0.56-6.1) 2.10 (0.5-1.2) 0.90 (0.5-1.1) 1.90 (0.56-6.1) 2.10 (0.5-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-1.2) 0.10 (0.60-		70–79 years	332	294 (88.6)	0.47 (0.32–0.69)	0.58 (0.37-0.90)	*	32	21 (65.6)	0.45 (0.21–0.97)	0.47 (0.20-1.11)	
thirdly thirdly <t< td=""><td></td><td>≥ 80 years</td><td>83</td><td>60 (72.3)</td><td>0.14 (0.08–0.23)</td><td>0.23 (0.12-0.44)</td><td>***</td><td>m</td><td>1 (33.3)</td><td>I</td><td>ı</td><td></td></t<>		≥ 80 years	83	60 (72.3)	0.14 (0.08–0.23)	0.23 (0.12-0.44)	***	m	1 (33.3)	I	ı	
Moni 29 24 50 24 50 24 50 24 50 24 50 24 50 24 50 24 50 5	Ethnicity											
Partire 12 11(66.7) 0.4/(0.27-0.80) 0.39(0.21-0.22) •• 21 15/14, 0.66 (0.35-1.7) 0.21(0.10-0.22) Atim 5 4(80) 2 25(1.04-2.2) 247(10) 0.66 (0.3-1.1) 0.71 (0.2-1.6) 0.26 (0.3-1.1) 0.71 (0.2-1.6) 0.72 (0.2-1.6) 0.72 (0.2-1.6) 0.72 (0.2-1.6) 0.76 (0.4-1.1) 0.76 (0.4-1.1) 0.76 (0.4-1.2) 0.76 (0.4-1.2) 0.76 (0.4-1.2) 0.76 (0.4-1.2) 0.76 (0.4-1.2) 0.76 (0.4-1.2) 0.76 (0.4-1.2) 0.76 (0.4-1.2) 0.76 (0.4-1.2) 0.76 (0.6-1.6) 0.76 (0.6-1.6) 0.76 (0.6-1.6) 0.76 (0.6-1.6) 0.76 (0.6-1.6) 0.76 (0.6-1.6) 0.76 (0.6-1.6) 0.76 (0.2-1.6) <th< td=""><td></td><td>Māori</td><td>299</td><td>284 (95.0)</td><td>1.26 (0.74–2.13)</td><td>1.17 (0.65–2.11)</td><td></td><td>38</td><td>33 (86.8)</td><td>1.75 (0.67–4.60)</td><td>1.59 (0.54–4.65)</td><td></td></th<>		Māori	299	284 (95.0)	1.26 (0.74–2.13)	1.17 (0.65–2.11)		38	33 (86.8)	1.75 (0.67–4.60)	1.59 (0.54–4.65)	
Asian 15 88 (6.4) 2.25 (109–5.29) 77 54 (0.1) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.10) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.12) 0.56 (0.3-1.13) 0.56 (0.3-1.10) Ware of Diagnois Year 2010/1 98 94 (60) 2.50 (1.425) 2.51 (1.225) 2.51 (1.225) 2.51 (1.225) 0.56 (0.3-1.13) 0.56 (0.3-1.2)		Pacific	128	111 (86.7)	0.47 (0.27–0.80)	0.39 (0.21-0.72)	**	21	15 (71.4)	0.66 (0.25–1.75)	0.31 (0.10-0.92)	*
Other 257 246(54.4) 1 1 471 337(72.1) 1 1 Mode of Diagnosis Screen-detected 218 206(94.7) 1 1 -<		Asian	195	188 (96.4)	2.25 (0.98–5.14)	2.45 (1.04-5.79)		77	54 (70.1)	0.76 (0.43–1.32)	0.56 (0.31-1.05)	
Unknown 5 4(800) - </td <td></td> <td>Other</td> <td>2575</td> <td>2406 (93.4)</td> <td>,</td> <td>-</td> <td></td> <td>471</td> <td>373 (79.2)</td> <td>, -</td> <td>, -</td> <td></td>		Other	2575	2406 (93.4)	,	-		471	373 (79.2)	, -	, -	
Mode of Diagnosis Streen-detected 128 2016 (94.7) 1 1 Year of Diagnosis Symptomatic 1074 977 (91.0) 0.58 (0.44–0.7) 0.51 (0.32–0.230) ••• 63 46 (7.3.0) 0.76 (0.41–13) 0.97 (0.46–195) Year of Diagnosis Year 2010/11 985 946 (96.0) 2.50 (1.73–3.52) 2.51 (1.70–3.230) ••• 63 46 (7.3.0) 0.76 (0.41–13) 0.97 (0.46–195) Year 2010/11 985 946 (96.0) 2.50 (1.73–3.52) 2.33 (1.44–2.302) 1.75 157 (71) 0.99 (0.35–1150) 0.97 (0.44–195) Year 2011/21 1192 078 (90.2) 1.08 (0.45–2.14) 0.82 (0.45–2.14) 0.82 (0.45–2.14) 0.87 (0.45–2.19) 0.97 (0.44–195) 0.97 (0.44–195) Wenopausal Status 7er 173 127 (70.0) 1 1 1 Perimenopausal 733 069 (2.23) 0.98 (0.45–2.14) 0.82 (0.45–2.14) 0.82 (0.45–2.14) 1 1 1 1 1 1 1 1 1 1 1 1 1<		Unknown	5	4 (80.0)	ı	ı		,	ı	1		
Screen-detected 218 2016 (9.4) 1 1 544 4.29 (78) 1 1 Year of Diagnosis Year 2010/11 985 946 (960) 250 (1,73-362) 251 (1,72-362) 42 (73) 0.76 (0,41-1)3) 0.97 (0,48-1)5) Year 2010/11 985 946 (960) 2.50 (1,73-362) 252 (1,70-325) 44 123 133 (105-284) 166 (0,97-283) Year 2014/15 1192 097 (902) 1 1 250 188 (732) 1 1 Year 2014/15 1192 076 (902) 1 1 250 188 (732) 1 1 1 Menopusal Status Permenopausal 731 057 (93-1) 087 (0,4-1) 3 057 (0,4-1) 1 1 1 Menopusal Status Permenopausal 733 107 (93-21) 087 (0,4-1) 1<	Mode of Diagnosis											
Symptomatic 104 977 (91.0) 0.58 (0.44–0.77) 0.52 (0.32–0.730) *** 6.3 4 (67.30) 0.76 (0.41–139) 0.97 (0.48–195) Year OEDagnosis Year Z011/13 1022 966 (9.63) 2.30 (1.43–3.62) *** 173 123 (1.05–2.84) 166 (0.97–2.83) Year Z011/13 1022 966 (9.48) 2.30 (1.44–2.82) 2.13 (1.47–3.02) *** 173 1.23 (1.05–2.84) 166 (0.97–2.83) Year Z011/13 1022 966 (9.48) 2.30 (1.4–2.82) 2.13 (1.47–3.02) *** 173 1.23 (1.05–2.84) 166 (0.97–2.83) Wenopausal Status Permenopausal 734 77 (95.2) 1 1 2.50 187 (7.1) 0.99 (0.63–1.52) 0.99 (0.6-1.62) Permenopausal 733 209 (92.7) 0.80 (0.45–1.01) 0.23 (0.45–2.16) 0.30 (0.67–1.52) 1		Screen-detected	2128	2016 (94.7)	,	, —		544	429 (78.9)	, -	-	
Verr of Dagnosis Verr of Dagnosis<		Symptomatic	1074	977 (91.0)	0.58 (0.44–0.77)	0.5 (0.35-0.730)	***	63	46 (73.0)	0.76 (0.41–1.39)	0.97 (0.48–1.95)	
Year 2010/1 985 946 (960) 250 (1/3 - 362) 223 (1.70 - 323) 113 (1.05 - 2.84) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.83) 166 (0.97 - 2.84) 166 (0.97 - 2.84) 166 (0.97 - 2.84) 166 (0.97 - 2.84) 166 (0.97 - 2.84) 166 (0.97 - 2.84) 166 (0.97 - 2.84) 166 (0.97 - 2.84) 160 (0.97 - 2.84)	Year of Diagnosis											
Year 2012/13 102 566 (648) 2.03 (1.44-2.85) 2.13 (1.47-3.08) *** 175 135 (77.1) 0.99 (0.65-1.65) 0.99 (0.65-1.62) Menopausal Status Peremenopausal 73 195 1078 (90.2) 1 250 188 (75.2) 1 1 1 Menopausal Status Peremenopausal 73 107 (95.4) 1 1 250 188 (75.2) 1<		Year 2010/11	985	946 (96.0)	2.50 (1.73–3.62)	2.52 (1.70-3.75)	***	182	152 (83.5)	1.73 (1.05–2.84)	1.66 (0.97–2.83)	
Year 2014/15 1195 1078 (90.2) 1 1 250 188 (75.2) 1 1 Menopausal Status Per-menopausal 74 75 (95.3) 0.98 (0.45-2.14) 0.82 (0.35-1.92) 187 148 (791) 1.51 (0.62-3.66) 194 (0.72-5.28) Per-menopausal 74 75 (95.3) 0.98 (0.45-2.14) 0.82 (0.35-1.92) 187 148 (791) 1.51 (0.62-3.66) 194 (0.72-5.28) Perimenopausal 77 165 (95.4) 1 1 1 30 21 (70.0) 1 1 1 Postmenopausal 770 678 (95.5) 2.06 (1.39-126) 0.97 (0.45-211) 390 306 (78.5) 140 (0.60-3.28) 112 (0.43-2.58) Facility Type Private 710 678 (95.5) 1.51 (0.94-2.44) 147 110 (74.8) 0.66 (0.43-1.05) 0.67 (0.38-1.117) Stage 1 1 1 1 1 1<10 (74.8)		Year 2012/13	1022	969 (94.8)	2.03 (1.44–2.85)	2.13 (1.47-3.08)	***	175	135 (77.1)	0.99 (0.63–1.56)	0.99 (0.6–1.62)	
Menopausal Status Pre-menopausal 794 757 (95.3) 0.38 (0.45-2.14) 0.82 (0.35-1.92) 187 148 (79.1) 1.51 (0.62-3.66) 194 (0.72-5.28) Peri-menopausal 175 167 (95.4) 1 1 30 21 (70.0) 1 112 (0.43-2.89) Facility Type Private 213 2069 (92.7) 0.61 (0.29-1.26) 0.97 (0.45-2.11) 390 306 (78.5) 1.40 (0.60-3.28) 1.12 (0.43-2.89) Facility Type Private 710 678 (95.5) 2.06 (1.39-3.05) 1.51 (0.94-2.44) 147 110 (74.8) 0.66 (0.43-1.02) 0.67 (0.38-1.17) Public 192 773 (91.6) 1 1 1 1 1 1 1 1 1 1 1 0.79 (0.43-1.102) 0.67 (0.38-1.17) 0.66 (0.43-1.02) 0.67 (0.38-1.17) 1		Year 2014/15	1195	1078 (90.2)	-	-		250	188 (75.2)	-	1	
Pre-menopausal 794 757 (95.3) 0.38 (0.45-2.14) 0.82 (0.35-1.92) 187 148 (79.1) 1.51 (0.62-3.56) 194 (0.72-5.28) Perimenopausal 175 167 (95.4) 1 1 30 21 (70.0) 1 1 FacilityType Private 710 657 (95.4) 1 1 30 306 (78.5) 1,40 (0.60-3.28) 1,12 (0.43-2.89) FacilityType Private 710 657 (95.4) 0.51 (0.29-1.26) 0.97 (0.45-2.11) 390 306 (78.5) 1,40 (0.60-3.28) 1,12 (0.43-2.89) FacilityType Private 710 657 (95.4) 1	Menopausal Status											
Peri-menopausal 175 167 (95.4) 1 1 30 21 (70.0) 1 1 Facility Type Post-menopausal 223 2069 (92.7) 0.61 (0.29-126) 0.97 (0.45-2.11) 390 306 (78.5) 1.40 (0.60-3.28) 11.10 (0.43-2.89) Facility Type Private 710 678 (95.5) 2.06 (1.39-3.05) 1.51 (0.94-2.44) 147 110 (74.8) 0.65 (0.43-1.03) 0.67 (0.38-1.117) Public 1925 1763 (91.6) 1 1 391 313 (80.1) 1 1 Stage 1 2 552 (97.4) - - - 69 52 (75.4) 0.79 (0.43-1.45) 0.63 (0.08-5.25) Stage 1 1 1 1 1 1 1 1 Stage 1 2 552 (97.4) - - - 69 52 (75.4) 0.79 (0.43-1.45) 0.63 (0.08-5.25) Stage 1 1 1 1 1 1 1 I.A 81		Pre-menopausal	794	757 (95.3)	0.98 (0.45–2.14)	0.82 (0.35–1.92)		187	148 (79.1)	1.51 (0.62–3.66)	1.94 (0.72–5.28)	
Post-menopaual 233 2069 (92.7) 0.61 (0.29-1.26) 0.97 (0.45-2.11) 390 306 (785) 1.40 (0.60-3.28) 11.1 (0.43-2.89) Facility Type Private 710 678 (95.5) 2.06 (1.39-3.05) 1.51 (0.94-2.44) 147 110 (74.8) 0.66 (0.43-1.03) 0.67 (0.38-1.17) Public 1925 1763 (91.6) 1 1 391 313 (60.1) 1 1 Unknowin 567 552 (97.4) - - 69 52 (75.4) 0.79 (0.43-1.45) 0.63 (0.08-5.25) Stage 1 2153 2001 (92.9) 1		Peri-menopausal	175	167 (95.4)	-	_		30	21 (70.0)	-	-	
Facility Type Facility Type 147 110 (748) 0.66 (0.43-1.03) 0.57 (0.38-1.17) Public 1925 1763 (91.6) 1 1 391 313 (80.1) 1 1 Public 1925 1763 (91.6) 1 1 391 313 (80.1) 1 1 Nenown 567 552 (97.4) - - 69 52 (75.4) 0.79 (0.43-1.45) 0.65 (0.08-5.25) Stage 1 2153 2001 (92.9) 1 1 1 1 1 Id 812 771 (95.0) 1.83 (1.22-27.4) 1.55 (0.88-2.71) 0.79 (0.43-1.45) 0.65 (0.08-5.25) Id 812 771 (95.0) 1.83 (1.22-27.4) 1.55 (0.88-2.71) 1.51 (0.94-3.43) 0.66 (0.43-1.45) 0.65 (0.08-5.25) Id 82 771 (95.0) 1.83 (1.22-27.4) 1.55 (0.88-2.71) 1.51 (0.94-2.43) 0.67 (0.34-1.45) 0.65 (0.68-5.25) Id 82 771 (95.0) 1.83 (1.22-2.48) 0.12 (0.24-3.43) 0.79 (0.43-1.45) 0.65 (0.96-2.45)		Post-menopausal	2233	2069 (92.7)	0.61 (0.29–1.26)	0.97 (0.45–2.11)		390	306 (78.5)	1.40 (0.60–3.28)	1.12 (0.43–2.89)	
Private 710 678 (95.5) 2.06 (1.39–3.05) 1.51 (0.94–2.44) 147 110 (74.8) 0.66 (0.43–1.03) 0.67 (0.38–1.17) Public 1925 1763 (91.6) 1 1 391 313 (80.1) 1 1 Unknown 567 552 (97.4) - - 69 52 (75.4) 0.63 (0.08–5.25) Stage 1 2153 2001 (92.9) 1 1 1 1 I:A 812 771 (95.0) 1.83 (1.22–2.74) 1.55 (0.88–2.71) 69 52 (75.4) 0.79 (0.43–1.45) 0.63 (0.08–5.25) I:B 812 771 (95.0) 1.83 (1.22–2.74) 1.55 (0.88–2.71) 1 1 1 I:B 18 176 (93.1) 0.99 (0.51–1.92) 0.86 (0.24–3.43) 0.63 (0.08–5.25) 0.66 (0.43–1.45) 0.63 (0.08–5.25) HER2 Status I:I 48 45 (93.3) 1.12 (0.24–3.43) 1.20 (0.41–2.47) 0.79 (0.41–2.43) 0.63 (0.08–5.25) HER2 Status I:I 0.09 (0.47–2.53) 1.20 (0.41–2.43) 1.20 (0.41–2	Facility Type											
Public 1925 1763 (91.6) 1 1 391 313 (80.1) 1 1 Unknown 567 552 (97.4) - - 69 52 (75.4) 0.79 (0.43-11.45) 0.63 (0.08-5.25) Stage 1 2153 2001 (92.9) 1 1 0.79 (0.43-11.45) 0.63 (0.08-5.25) IIA 812 771 (95.0) 1.83 (1.22-2.74) 1.55 (0.88-2.71) 0.79 (0.43-11.45) 0.63 (0.08-5.25) IIB 189 176 (93.1) 0.99 (0.51-1.92) 0.88 (0.29-2.48) 1.12 (0.43-1.43) 0.63 (0.08-5.25) IIIA 48 45 (93.8) 1.12 (0.34-3.65) 0.90 (0.24-3.43) 1.12 (0.41-2.47) 0.79 (0.43-1.45) 0.63 (0.08-5.25) HER2 Status Equivocal 100 94 (94.0) 1.09 (0.47-2.53) 1.20 (0.41-2.47) 1.20 (0.41-2.47) 1.20 (0.41-2.47) 1.20 (0.41-2.47) 1.20 (0.41-2.47) 1.20 (0.41-2.47) 1.20 (0.41-2.47) 1.20 (0.41-2.47) 1.20 (0.41-2.43) 1.20 (0.41-2.43) 1.20 (0.41-2.43) 1.20 (0.41-2.43) 1.20 (0.41-2.43) 1.20 (0.41-2.43) 1.20 (0.41-2.43		Private	710	678 (95.5)	2.06 (1.39–3.05)	1.51 (0.94–2.44)		147	110 (74.8)	0.66 (0.43–1.03)	0.67 (0.38–1.17)	
Unknown 567 552 (97.4) - - 69 52 (75.4) 0.79 (0.43-1.45) 0.63 (0.08-5.25) Stage I 2 2 2 1 1 0.79 (0.43-1.45) 0.63 (0.08-5.25) Stage I 2 2 2 1 1 1 IA 812 771 (95.0) 1.83 (1.22-2.74) 1.55 (0.88-2.71) 0.79 (0.43-1.45) 0.63 (0.08-5.25) IB 189 176 (93.1) 0.99 (0.51-1.92) 0.85 (0.29-2.48) 1.12 (0.34-3.43) IIA 48 45 (93.8) 1.12 (0.34-3.65) 0.90 (0.24-3.43) HER2 Status Equivocal 100 94 (94.0) 1.09 (0.47-2.53) 1.20 (0.41-2.47) Negative 2729 2554 (93.6) 1 1.90 (0.47-2.53) 1.20 (0.41-2.47) Positive 269 258 (95.9) 1.78 (0.93-3.42) 1.19 (0.6-2.39)		Public	1925	1763 (91.6)	-			391	313 (80.1)	-	-	
Stage I 2153 2001 (92.9) 1 1 IIA 812 771 (95.0) 1.83 (1.22-2.74) 1.55 (0.88-2.71) IIB 18 176 (93.1) 0.99 (0.51-1.92) 0.85 (0.29-2.48) IIIA 48 45 (93.1) 0.99 (0.51-1.92) 0.85 (0.29-2.48) IIIA 48 45 (93.8) 1.12 (0.34-3.65) 0.90 (0.24-3.43) HER2 Status Equivocal 100 94 (94.0) 1.09 (0.47-2.53) 1.20 (0.41-2.47) Negative 2729 2554 (93.6) 1 100 (0.41-2.47) 1 Positive 269 258 (95.9) 1.78 (0.93-3.42) 1.19 (0.6-2.39)		Unknown	567	552 (97.4)	I	I		69	52 (75.4)	0.79 (0.43–1.45)	0.63 (0.08–5.25)	
I 2153 2001 (92.9) 1 1 IIA 812 771 (95.0) 1.83 (122–2.74) 1.55 (088–2.71) IIB 189 176 (93.1) 0.99 (0.51–1.92) 0.85 (0.29–2.48) IIIA 48 45 (93.8) 1.12 (0.34–3.65) 0.90 (0.24–3.43) HER2 Status Equivocal 100 94 (94.0) 1.12 (0.34–3.65) 0.90 (0.24–3.43) Negative 2729 2554 (93.6) 1.09 (0.47–2.53) 1.20 (0.41–2.47) Positive 269 258 (95.9) 1.78 (0.93–3.42) 1.19 (0.6–2.39)	Stage											
IIA 812 771 (95.0) 1.83 (1.22–2.74) 1.55 (0.88–2.71) IIB 189 176 (93.1) 0.99 (0.51–1.92) 0.85 (0.29–2.48) IIIA 48 45 (93.8) 1.12 (0.34–3.65) 0.90 (0.24–3.43) HER2 Status Equivocal 100 94 (94.0) 1.09 (0.47–2.53) 1.20 (0.41–2.47) Negative 2729 2554 (93.6) 1 1.9 (0.64–2.39) Positive 269 258 (95.9) 1.78 (0.93–3.42) 1.19 (0.6–2.39)			2153	2001 (92.9)	, -	-						
IIB 189 176 (93.1) 0.99 (0.51-1.92) 0.85 (0.29-2.48) IIIA 48 45 (93.8) 1.12 (0.34-3.45) 0.90 (0.24-3.43) HER2 Status Equivocal 100 94 (94.0) 1.09 (0.47-2.53) 1.20 (0.41-2.47) Negative 2729 2554 (93.6) 1 1 1 Positive 269 258 (95.9) 1.78 (0.93-3.42) 1.19 (0.6-2.39)		IIA	812	771 (95.0)	1.83 (1.22–2.74)	1.55 (0.88–2.71)						
IIIA 48 45 (93.8) 1.12 (0.34-3.65) 0.90 (0.24-3.43) HER2 Status Equivocal 100 94 (94.0) 1.09 (0.47-2.53) 1.20 (0.41-2.47) Negative 2729 2554 (93.6) 1 1 1 Positive 269 258 (95.9) 1.78 (0.93-3.42) 1.19 (0.6-2.39)		IIB	189	176 (93.1)	0.99 (0.51–1.92)	0.85 (0.29–2.48)						
HER2 Status Equivocal 100 94 (94.0) 1.09 (0.47–2.53) 1.20 (0.41–2.47) Negative 2729 2554 (93.6) 1 1. Positive 269 258 (95.9) 1.78 (0.93–3.42) 1.19 (0.6–2.39)		IIIA	48	45 (93.8)	1.12 (0.34–3.65)	0.90 (0.24–3.43)						
Equivocal 100 94 (94.0) 1.09 (0.47–2.53) 1.20 (0.41–2.47) Negative 2729 2554 (93.6) 1 Positive 269 258 (95.9) 1.78 (0.93–3.42) 1.19 (0.6–2.39)	HER2 Status											
Negative 2729 2554 (93.6) 1 1 Positive 269 258 (95.9) 1.78 (0.93–3.42) 1.19 (0.6–2.39)		Equivocal	100	94 (94.0)	1.09 (0.47–2.53)	1.20 (0.41–2.47)						
Positive 269 258 (95.9) 1.78 (0.93–3.42) 1.19 (0.6–2.39)		Negative	2729	2554 (93.6)	-	_						
		Positive	269	258 (95.9)	1.78 (0.93–3.42)	1.19 (0.6–2.39)						

Current Control Current Contro Current Control Current Con								in a como in cin		
interfacional control interfactor interfactor<	Category		Total	Adjuvant	Crude OR	Adjusted OR	Total	Adjuvant	Crude OR	Adjusted OR
Grade Unknown 101 87 (82.7) - - 1 033 56 (91.7) 1 1 1 2 1454 36 (93.6) 1.30 (0.96-178) 1.22 (1.08-2.13) 1.30 (0.96-178			z	radiotherapy n (%)	(95% CI)	(95% CI)	z	radiotherapy n (%)	(95% CI)	(95% CI)
Gade 1 103 56 (51) 1 1 2 144 151 (56) 1.30 (36-15) 1.31 (36-15) 1.30 (36-15)<		Unknown	104	87 (83.7)	1					
1 1 1 1 1 2 4454 156 (93.2) 1 1 1 3 6.2 68(9.1.2) 1 1 1 3 6.2 68(9.2.) 1 1 1 5 6.4 156 (93.2) 1 1 1 5 6.4 18 (73.3) - - 1 1 1 1 9 1 1 1 1 1 1 1 1 1	Grade									
2 144 130 (036-1/3) 122 (108-2.13) 14 50e 12 130 (036-1/3) 130 (036-1/3) 120 (147-32) 140 51e 68(64) 234 (147-32) 140 (170-1/3) 13 (173-1/3) 140 51e 68(964) 130 (036-1/3) 16 (038-1/3) 17 (17-1/3) 17 11-10mm 160 130 (139-1/3) 16 (038-1/3) 17 (00-1/3) 17 (00-1/3) 11-10mm 10 10 100 (103-26) 10.4 (103-26) 12 (00-1/3) 11-10mm 10 10 10 10 10 10 11-10mm 10 10 10 10 10 10 11-10mm 10 10 10 10 10 10 11-10mm 260 247/132 10 10 10 10 11-10mm 20 19(50) - - 1 1 1 11-10mm 20 19(50) 20 10 10 10 1 <td></td> <td></td> <td>1053</td> <td>966 (91.7)</td> <td>,</td> <td>-</td> <td></td> <td></td> <td></td> <td></td>			1053	966 (91.7)	,	-				
3 672 68/96.4/1 2.34(1.47-3.72) 2.49(1.39-4.46) *** Size Unknown 23 8(73.3) - - - - 11-19 <mm< td=""> 601 1394(93.2) 11.6(036-1.57) 137(03-1.79) 137(03-1.79) 11-19<mm< td=""> 601 1394(93.2) 1.6(103-2.61) 1.6(038-3.86) 1.5(038-3.86) 11-19<mm< td=""> 77 657 94.1) 1.6(103-2.61) 1.76(038-3.86) 1.50(038-3.86) 11-19<mm< td=""> 76 532 631 95.25 1 1.70(03-3.36) Nome 2.60 323 631 95.25 1 1.6(03-3.24) 0.5(03-3.54) Nome 2.61 1.61 (03-2.61) 0.65 (03-1.51) 0.66 (03-1.51) 0.65 (03-1.51) Nome 2.03 2.95 (9.3) 1.21 (02.2) 0.21 (03.2) 0.21 (03.2) Nome 2.03 2.99 (9.3) 1.21 (02.2) 0.21 (03.2) 0.21 (03.2) Nome 2.03 2.99 (9.3) 1.21 (02.2) 0.21 (03.2) 0.21 (03.2) Nome 2.0</mm<></mm<></mm<></mm<>		2	1454	1361 (93.6)	1.30 (0.96–1.76)	<u>1.52 (1.08–2.13)</u> **				
Size Unknown 23 18 (78.3) - - Aller < 10mm		c	672	648 (96.4)	2.34 (1.47–3.72)	2.49 (1.39-4.46) ***	¥			
Site Limm 84 814(92) 1 1 Limplouscular Invasion 11-9 mm 100 156(035-157) 127(03-129) Limplouscular Invasion No 556 2471(93.2) 1 1 Ves 332 503(94.5) 1 1 1 Ves 332 503(94.5) 1 1 1 Unknown 20 19(95.0) - 1 1 Unknown 20 19(95.0) - 1 3 Unknown 20 279(62.5) 143(078-261) 0 0 0 Unknown 20 19(95.0) - - - - Unknown 62 54(12.5) 1 0 0 0 0 Rual 13 143(078-261) 1 0 0 0 0 0 Unknown 62 54(92.0) 1 0 0 0		Unknown	23	18 (78.3)	ı	ı				
<10 mm	Size									
III-19mm I601 I504 (33) I16 (086-157) I27 (09-139) Apmphovascular Invasion No 250 2471 (932) I I I I No 2550 2471 (932) I <		< 10 mm	884	814 (92.1)	1	1				
S20 mm 717 675 (9.1) 1.54 (103-2.61) 1.76 (0.78-3.96) Lymphoxascular Invasion No 2550 2471 (93.2) 1 1 Ves 332 503 (49.5) 1.22 (0.82-1.83) 0.95 (0.59-1.51) 1 Ves 325 503 (49.5) 1.22 (0.82-1.83) 0.95 (0.59-1.51) 1 Unknown 20 19 (95.0) - - - - Both positive 2141 2006 (93.7) 1 1 1 1 One positive 2141 2006 (93.7) 1 1 1 1 Murality Both positive 2141 2006 (93.7) 1 1 1 One positive 2141 2006 (93.7) 1 1 1 1 Unknown 162 144 (88) - - - - - Deprivation Status 803 203 (0.57-1.14) 0.76 (0.38-1.47) 0.76 (0.38-1.47) - Deprivation Status 812 0.31 (0.74-1.47)		11-19 mm	1601	1504 (93.9)	1.16 (0.86–1.57)	1.27 (0.9–1.79)				
Lymphovascular Invision No 2550 2471 (33.2) 1 1 Yes 32 503 (94.5) 1.22 (082-1.83) 0.95 (0.59-1.51) 0.95 (0.59-1.51) Verknown 20 19 (55.0) - - - Hormone receptor Both negative 290 279 (66.2) 1.43 (0.78-2.61) 0.87 (0.43-1.75) Both negative 290 279 (66.2) 1.43 (0.78-2.61) 0.87 (0.43-1.75) 0.87 (0.43-1.75) Both negative 290 279 (66.2) 1.43 (0.78-2.61) 0.87 (0.43-1.75) 0.87 (0.43-1.75) Both negative 291 1.41 (3.76) 1.43 (0.78-2.14) 0.39 (0.59-1.47) 0.95 (0.59-1.47) Ore pos/one neg 609 564 (92.6) 0.81 (0.57-1.14) 0.30 (0.59-1.47) 0.76 (0.38-1.49) Unknown 162 144 (88.9) - - - - Bural 151 139 (22.1) 0.81 (0.57-1.14) 0.30 (0.59-1.47) 0.76 (0.38-1.49) Unknown 162 144 (88.9) - - - - <td></td> <td>> 20 mm</td> <td>717</td> <td>675 (94.1)</td> <td>1.64 (1.03–2.61)</td> <td>1.76 (0.78–3.98)</td> <td></td> <td></td> <td></td> <td></td>		> 20 mm	717	675 (94.1)	1.64 (1.03–2.61)	1.76 (0.78–3.98)				
No 25/3 2471 (93.2) 1 1 Yes 332 503 (94.5) 1.22 (0.22-1.83) 0.95 (0.59-1.51) Virtex 332 503 (94.5) 1.22 (0.22-1.83) 0.95 (0.59-1.51) Hormone receptor Both negative 20 19 (55.0) - - Both positive 2141 2006 (93.7) 1 1 1 Cone pos/one meg 609 564 (92.6) 0.81 (0.57-1.14) 0.93 (0.43-1.75) Buth positive 2141 2006 (93.7) 1 1 1 Unknown 162 144 (88.9) - - - Unknown 152 139 (92.1) 0.80 (0.43-1.47) 0.76 (0.38-1.49) Unknown 152 144 (88.9) - - - Unknown 152 139 (92.1) 0.80 (0.43-1.77) 0.76 (0.38-1.49) Unknown 183 172 (92.9) 1 1 1 Unknown 183 172 (92.9) 1 1 1 D	Lymphovascular Invasion									
Yes 532 503 (945) 1.22 (0.82–1.81) 0.95 (0.59–1.51) Hormone receptor Both negative 20 19 (95.0) - - Both negative 290 279 (96.2) 1.43 (0.78–2.61) 0.87 (0.43–1.75) - Both positive 290 279 (96.2) 1.43 (0.78–2.61) 0.87 (0.43–1.75) - Both positive 200 54 (92.6) 0.81 (0.57–1.14) 0.93 (0.59–1.47) - Unknown 162 144 (88.9) - - - - Mural 151 139 (92.1) 0.81 (0.57–1.14) 0.93 (0.59–1.47) - Unknown 162 144 (88.9) - - - - Unknown 120 139 (92.1) 0.81 (0.57–1.14) 0.95 (0.58–1.47) 0.76 (0.38–1.49) Unknown 120 144 (83.9) - - - Unknown 120 133 (0.52–1.14) 0.76 (0.38–1.49) Unknown 120 Unknown 120 133 (0.22) 0.81 (0.57–1.14)		No	2650	2471 (93.2)	,	-				
Hormone receptor 20 19 (95.0) - - Hormone receptor Both negative 290 279 (95.2) 143 (0.28–261) 087 (0.43–1.75) Both negative 291 2006 (93.7) 1 1 1 One positive 2141 2006 (93.7) 1 1 1 One positive 2141 2006 (93.7) 1 0.30 (0.59–1.47) 0.30 (0.59–1.47) One positive 2141 2006 (93.7) 1 1 1 1 One positive 151 139 (92.1) 081 (0.57–1.14) 0.30 (0.59–1.47) 0.41 47) Rurality Rural 151 139 (92.1) 081 (0.44–1.47) 0.6 (0.38–1.49) Unknown 152 144 (83.9) - - - Unknown 152 139 (92.1) 0.8 (0.44–1.47) 0.76 (0.38–1.49) Unknown 1208 1142 (94.5) - - - NZDep Quintile 440 411 (93.4) 1.04 (0.63–1.74) 1.03 (0.6–1.76)		Yes	532	503 (94.5)	1.22 (0.82–1.83)	0.95 (0.59–1.51)				
Hormone receptor Both negative 200 279 (96.2) 1.43 (0.78-261) 0.87 (0.43-1.75) Both negative 2141 2006 (93.37) 1 1 Both positive 2141 2006 (93.37) 1 1 One pos/one neg 609 564 (92.6) 0.81 (0.57-1.14) 0.93 (0.59-1.47) Unknown 162 144 (88.9) - - - Unban 151 139 (92.1) 0.8 (0.44-1.47) 0.76 (0.38-1.49) Urban 154 171 (92.9) 1 1 Urban 1843 171 (29.2) 1 1 Unknown 1208 1142 (94.5) - - NZDep Quintile 440 411 (93.4) 1 1 NZDep Quintile 371 129 (95-1.16) 105 (0.6-1.76) 105 (0.6-1.76) NZDep Quintile 371 143 (0.35-1.63) 105 (0.6-1.76) 105 (0.6-1.84) 103 (0.6-1.76) NZDep Quintile 371 293 (0.30) 050 (0.36-1.61) 050 (0.36-1.76) 117 (0.39-3.49)		Unknown	20	19 (95.0)	ı	ı				
Both negative 290 279 (96.2) 1.43 (0.73–1.75) Both negative 290 279 (96.2) 1.43 (0.73–1.75) Both positive 2141 2006 (93.7) 1 1 One pos/one neg 609 564 (92.6) 0.81 (0.57–1.14) 0.93 (0.59–1.47) Unknown 162 144 (88.9) - - - Rural 151 139 (92.1) 0.8 (0.44–147) 0.76 (0.38–1.49) Unknown 163 1712 (92.9) 1 1 Unknown 108 144 (147) 0.76 (0.38–1.49) NZDep Quintile 440 411 (93.4) 1 1 NZDep Quintile 470 439 (93.2) 1.04 (0.63–1.74) 103 (0.6–1.36) NZDep Quintile 370 399 (0.59–1.65) 105 (0.6–1.84) 1 1 NZDep Quintile 366 357 (90.2) 065 (0.40–1.07) 061 (0.34–1.09) 1 1 NZDep Quintile 366 357 (90.2) 1.46 (0.55–3.33) 1.17 (0.39–3.49) 1.17 (0.39–3.49) 1.17 (0.39–3.49) </td <td>Hormone receptor</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Hormone receptor									
Both positive 2141 2006 (93.7) 1 1 One pos/one neg 609 564 (92.6) 0.81 (0.57-1.14) 0.93 (0.59-1.47) Unknown 162 144 (88.9) - - - Unknown 162 144 (88.9) - - - Rural 151 139 (92.1) 0.8 (0.44-147) 0.76 (0.38-1.49) - Urban 1843 1712 (92.9) 1 1 - - Unknown 1208 1142 (94.5) - - - - Deprivation Status NZDep Quintile 400 411 (93.4) 1 1 1 NZDep Quintile 471 439 (93.2) 104 (0.63-1.76) 065 (0.40-1.07) 061 (0.34-1.09) NZDep Quintile 377 (90.2) 059 (0.59-1.63) 107 (0.39-3.49) 177 (0.39-3.49) NZDep Quintile 362 377 (90.2) 065 (0.40-1.07) 061 (0.34-1.09) 051 (0.34-1.09) NZDep Quintile 362 97 (95.1) 1.45 (0.55-3.33) 1.17 (0.39-3.49)		Both negative	290	279 (96.2)	1.43 (0.78–2.61)	0.87 (0.43–1.75)				
Che pos/one neg 609 564 (92.6) 031 (0.57-1.14) 0.93 (0.59-1.47) Unknown 162 144 (88.9) - - Rurality Rural 151 139 (92.1) 08 (0.44-147) 0.76 (0.38-1.49) Rural 151 139 (92.1) 08 (0.44-147) 0.76 (0.38-1.49) - Urban 1843 171 (92.9) 1 1 1 Urban 1843 171 (92.9) 1 1 1 Unknown 1208 1142 (94.5) - - - Deprivation Status NZDep Quintile 1 400 411 (93.4) 1 1 NZDep Quintile 2 529 493 (93.2) 104 (063-1.74) 103 (6-1.76) NZDep Quintile 3 471 439 (93.2) 099 (059-1.65) 105 (06-1.84) NZDep Quintile 4 396 357 (90.2) 065 (0.40-1.07) 061 (0.34-1.09) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55383) 1.17 (0.39349) Unknown 1264 1196 (94.6) - - -		Both positive	2141	2006 (93.7)	-	1				
Unknown 162 144 (8.9) - - Rurality 151 139 (92.1) 0.8 (0.44-14.7) 0.76 (0.38-1.49) Rural 151 139 (92.1) 0.8 (0.44-14.7) 0.76 (0.38-1.49) Urban 1843 1712 (92.9) 1 1 Deprivation Status NZDep Quintile 1 440 411 (93.4) 1 1 NZDep Quintile 2 529 493 (93.2) 1.04 (063-1.74) 1.03 (06-1.76) NZDep Quintile 2 367 (93.2) 0.99 (059-1.65) 1.05 (06-1.84) NZDep Quintile 5 102 97 (93.2) 0.99 (059-1.65) 1.05 (06-1.84) Urbnown 1264 1196 (94.6) - - -		One pos/one neg	609	564 (92.6)	0.81 (0.57–1.14)	0.93 (0.59–1.47)				
Rurality Rural 151 139 (92.1) 0.8 (0.44-1.47) 0.76 (0.38-1.49) Urban 1843 1712 (92.9) 1 1 Urban 1843 1712 (92.9) 1 1 Urban 1843 1712 (92.9) 1 1 Urban 1823 1712 (92.9) 1 1 Deprivation Status NZDep Quintile 1 440 411 (93.4) 1 1 NZDep Quintile 2 52.9 493 (93.2) 1.04 (0.63-1.74) 1.03 (0.6-1.76) NZDep Quintile 2 471 439 (93.2) 0.09 (0.59-1.65) 1.05 (0.6-1.84) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55-3.83) 1.17 (0.39-3.49) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55-3.83) 1.17 (0.39-3.49) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55-3.83) 1.17 (0.39-3.49) Unknown 1264 1196 (94.6) - - -		Unknown	162	144 (88.9)	I	ı				
Rural 151 139 (92.1) 0.8 (0.44-1.47) 0.76 (0.38-1.49) Urban 1843 1712 (92.9) 1 1 Unknown 1208 1142 (94.5) - - Deprivation Status NZDep Quintile 1 440 411 (93.4) 1 1 NZDep Quintile 2 529 493 (93.2) 1.04 (0.63-1.74) 1.03 (0.6-1.76) NZDep Quintile 2 529 493 (93.2) 0.99 (0.59-1.65) 1.05 (0.6-1.84) NZDep Quintile 2 367 (90.2) 0.65 (0.40-1.07) 0.61 (0.34-1.09) 0.61 (0.34-1.09) NZDep Quintile 2 102 97 (95.1) 1.45 (0.55-3.83) 1.17 (0.39-3.49) Unknown 1264 1196 (94.6) - - -	Rurality									
Urban 1843 1712 (92.9) 1 1 Deprivation Status Unknown 1208 1142 (94.5) - - Deprivation Status NZDep Quintile 1 440 411 (93.4) 1 1 NZDep Quintile 1 440 411 (93.4) 1 1.03 (0.6-1.76) 1.03 (0.6-1.76) NZDep Quintile 2 529 493 (93.2) 0.99 (0.59-1.65) 1.03 (0.6-1.76) 1.05 (0.6-1.84) NZDep Quintile 3 471 439 (93.2) 0.99 (0.59-1.65) 1.05 (0.6-1.84) 1.17 (0.39-3.49) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55-3.83) 1.17 (0.39-3.49) NZDep Quintile 5 102 97 (95.6) - - - Unknown 1264 1196 (94.6) - - -		Rural	151	139 (92.1)	0.8 (0.44–1.47)	0.76 (0.38–1.49)				
Unknown 1208 1142 (94.5) - - - Deprivation Status NZDep Quintile 1 440 411 (93.4) 1 1 NZDep Quintile 2 529 493 (93.2) 1.04 (063-1.74) 1.03 (0.6-1.76) NZDep Quintile 2 771 439 (93.2) 0.99 (059-1.65) 1.03 (0.6-1.84) NZDep Quintile 4 396 357 (90.2) 0.65 (0.40-1.07) 0.61 (0.34-1.09) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55-3.83) 1.17 (0.39-3.49) Unknown 1264 1196 (94.6) - - -		Urban	1843	1712 (92.9)	,	-				
Deprivation Status NZDep Quintile 1 440 411 (93.4) 1 1 NZDep Quintile 2 529 493 (93.2) 1.04 (0.63–1.74) 1.03 (0.6–1.76) NZDep Quintile 2 529 493 (93.2) 0.99 (0.59–1.65) 1.03 (0.6–1.76) NZDep Quintile 4 396 357 (90.2) 0.99 (0.59–1.65) 1.05 (0.6–1.84) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55–3.83) 1.17 (0.39–3.49) Unknown 1264 1196 (94.6) - - -		Unknown	1208	1142 (94.5)	ı	ı				
NZDep Quintile 1 440 411 (93.4) 1 1 1 NZDep Quintile 2 529 493 (93.2) 1.04 (0.63-1.74) 1.03 (0.6-1.76) NZDep Quintile 3 471 439 (93.2) 0.99 (0.59-1.65) 1.05 (0.6-1.84) NZDep Quintile 4 396 357 (90.2) 0.65 (0.40-1.07) 0.61 (0.34-1.09) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55-3.83) 1.17 (0.39-3.49) Unknown 1264 1196 (94.6)	Deprivation Status									
NZDep Quintile 2 529 493 (93.2) 1.04 (0.63–1.74) 1.03 (0.6–1.76) NZDep Quintile 3 471 439 (93.2) 0.99 (0.59–1.65) 1.05 (0.6–1.84) NZDep Quintile 4 396 357 (90.2) 0.65 (0.40–1.07) 0.61 (0.34–1.09) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55–3.83) 1.17 (0.39–3.49) Unknown 1264 1196 (94.6)		NZDep Quintile 1	440	411 (93.4)	,	-				
NZDep Quintile 3 471 439 (93.2) 0.99 (0.59–1.65) 1.05 (0.6–1.84) NZDep Quintile 4 396 357 (90.2) 0.65 (0.40–1.07) 0.61 (0.34–1.09) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55–3.83) 1.17 (0.39–3.49) Unknown 1264 1196 (94.6)		NZDep Quintile 2	529	493 (93.2)	1.04 (0.63–1.74)	1.03 (0.6–1.76)				
NZDep Quintile 4 396 357 (90.2) 0.65 (0.40–1.07) 0.61 (0.34–1.09) NZDep Quintile 5 102 97 (95.1) 1.45 (0.55–3.83) 1.17 (0.39–3.49) Unknown 1264 1196 (94.6)		NZDep Quintile 3	471	439 (93.2)	0.99 (0.59–1.65)	1.05 (0.6–1.84)				
NZDep Quintile 5 102 97 (95.1) 1.45 (0.55–3.83) 1.17 (0.39–3.49) Unknown 1264 1196 (94.6)		NZDep Quintile 4	396	357 (90.2)	0.65 (0.40-1.07)	0.61 (0.34–1.09)				
Unknown 1264 1196 (94.6)		NZDep Quintile 5	102	97 (95.1)	1.45 (0.55–3.83)	1.17 (0.39–3.49)				
		Unknown	1264	1196 (94.6)	ı	ı				

radiotherapy was higher in registrations before 2014, and those having higher grade tumours (Table 3; Fig. 2b).

For the in situ group, similarly, the receipt of adjuvant radiotherapy was significantly less likely in Pacific women, showing a larger effect in multivariable analysis: OR 0.31 (95% CI 0.10–0.92), with no significant associations with Māori and Asian, compared to Other ethnicity. Adjuvant radiotherapy was also less likely to be received in younger women of \leq 49 years than older women (Table 3).

Regarding referral status among women who underwent BCS without adjuvant radiotherapy, 'not referred - deemed not necessary' category was the most common (8%), followed by 'referred - patient declined' (5%) (Table 4). In the category 'not referred - deemed not necessary', Asian women contributed the highest percentage (13%) compared to other ethnic groups (7–9%); and so did the women aged≥80 years (23%) compared to other age groups (8–9%). In the category 'referred - patient declined', Pacific women contributed the highest proportion (10%) compared to other ethnic groups (3–7%); and so did the women aged≥80 years (14%) compared to other age groups (4–6%).

Discussion

Our research, for the first time, has examined the treatment decision for mastectomy and adjuvant radiotherapy after breast conserving surgery (BCS) in the selected cohort of New Zealand women who were eligible for BCS, focusing on ethnic differences. We assessed 5520 eligible women, including 4541 invasive and 979 in situ patients over a six-year period.

Receipt of mastectomy in BCS eligible women

We found that 22.2% of all BCS-eligible women in our study received mastectomy during 2010–2015, with

a higher proportion in women with invasive disease (24.5%) and a much lower proportion in those with in situ disease (11.8%). These mastectomy rates appear lower than a US national study of 1.2 million BCS-eligible women, which reported a mastectomy rate of 35.5% overall – 37.9% invasive and 19.3% in situ [27]. A 2009–2014 Australian study of 24,666 breast cancer patients who underwent breast surgery also reported a higher mastectomy rate of 36%, although eligibility for BCS was unknown [28].

Our study showed that Asian women were twice as likely to receive a mastectomy for invasive disease compared to women of Other ethnicity (p < 0.001), but no significant difference was seen for Māori and Pacific women. The finding of the higher mastectomy rates for Asian is supported by a previous New Zealand study [29]. While the specific underlying reasons for this are unknown, the potentially related factors may include smaller average breast size in relation to tumour size, cultural views, and younger age at diagnosis in Asian women with breast cancer, compared to New Zealand European women [29]. A previous study involving women with tumour size up to 50 mm evidenced that Māori were significantly more likely to receive mastectomy overall than Other ethnicity (OR 1.45, 95% CI 1.07-1.95) [15]. Māori and Pacific women were also frequently diagnosed via the symptomatic pathway, resulting in more advanced disease and more aggressive treatment in these groups [5, 15]. In our study using a BCS restricted cohort, surprisingly, the proportion of screen-detected cancers was higher for Māori and Pacific women than that of Asian and Other ethnicity; and screen-detected cancers were associated with decreased likelihood of mastectomy. Our findings that receipt of mastectomy for Māori and Pacific women was similar to that seen for Other ethnicities may result from the exclusion of larger or multifocal tumours from

Table 4 Radiotherapy referral data for women who underwent BCS, by ethnicity and age group

	Radiother-	Radiotherapy	not received						Unknown	Total
	apy received	Not referred -			Not yet	Referred -				
		Deemed not necessary	Patient declined	Patient unfit		Deemed not necessary	Patient declined	Patient unfit		
Total	3526 (82%)	361 (8%)	1 (0%)	2 (0%)	109 (3%)	89 (2%)	196 (5%)	0 (0%)	5(0%)	4292
Ethnicity										
Māori	317 (84%)	28 (7%)	0 (0%)	0 (0%)	11 (3%)	8 (2%)	11 (3%)	1 (0%)	0 (0%)	376
Pacific	126 (75%)	15 (9%)	0 (0%)	0 (0%)	3 (2%)	6 (4%)	17 (10%)	0 (0%)	1 (1%)	168
Asian	246 (76%)	42 (13%)	0 (0%)	0 (0%)	8 (2%)	5 (2%)	21 (7%)	0 (0%)	0 (0%)	322
Others	2831 (83%)	276 (8%)	1 (0%)	2 (0%)	87 (3%)	68 (2%)	147 (4%)	0 (0%)	4 (0%)	3418
Unknown	6 (75%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (25%)	0 (0%)	1 (13%)	0 (0%)	8
Age group										
≤49 years	758 (82%)	80 (9%)	0 (0%)	2 (0%)	31 (3%)	15 (2%)	40 (4%)	0 (0%)	1 (0%)	927
50–69 years	2386 (84%)	222 (8%)	0 (0%)	0 (0%)	60 (2%)	50 (2%)	113 (4%)	1 (0%)	1 (0%)	2833
70–79 years	319 (77%)	32 (8%)	1 (0%)	0 (0%)	14 (3%)	18 (4%)	26 (6%)	1 (0%)	3 (1%)	414
≥80 years	63 (53%)	27 (23%)	0 (0%)	0 (0%)	4 (3%)	6 (5%)	17 (14%)	0 (0%)	1 (1%)	118

the study sample. We note that breast density and breast volume, on which the data were unavailable in our study, may be relevant to the choice of surgery in different ethnic groups.

Our research indicated a higher rate of mastectomy in women of older age, symptomatic disease, higher stage, hormone receptor-negative, and HER2-positive, in accordance with previous research [15, 30, 31]. An earlier study in the Auckland and Waikato regions [16] found that receipt of mastectomy also varied by socioeconomic status and facility type, for which, our study showed no significant variation. Our finding of non-variation for rurality may partly be explained by the coverage of the NZBCR, which at the point of data extraction has only just consolidated the Auckland, Waikato, Wellington and Christchurch datasets, while including other cancer centres (e.g., Southern and Midcentral regions) may provide a better comparison for rural populations.

Our study observed a decrease in receipt of mastectomy over the 6-year period. This reflects a change in practice and international trend of increasing BCS [32–34], research evidence and growing experience with oncoplastic breast techniques that allow resection of larger breast volumes while retaining good aesthetic outcomes. The change may also be related to greater use of neoadjuvant therapy which can reduce tumour size and permit consideration of BCS as a surgical option in a larger number of patients.

Receipt of adjuvant radiotherapy following BCS

Our study found that most women (91.1%) who had BCS received adjuvant radiotherapy, with a higher rate for invasive disease (93.5%) than for in situ disease (78.8%). The rate of adjuvant radiotherapy after BCS varies widely across different studies and populations; for example, it was 66.2% in a US breast cancer cohort [18], and 81% in an Australian breast cancer cohort [28]. These international studies suggested the lower uptake of adjuvant radiotherapy in certain patient groups may be related to older age, comorbidities, lower socioeconomic position, and distance to radiotherapy centre.

Our analysis revealed that adjuvant radiotherapy was much lower in Pacific women and higher in Asian women with invasive disease than those of Other ethnicity, showing no significant difference for Māori, after adjusting for other demographic and clinicopathological factors. Our research also observed that a higher proportion of Pacific women declined radiotherapy after being referred compared to women of the reference Other ethnic group. Potential reasons for the lower rate of radiotherapy in Pacific women include health literacy, cultural views, socioeconomic inequities and health systems factors such as lack of continuity, difficulty in access and critical shortage in Pacific healthcare workforce [35]; whereas potential reasons for the higher rate of adjuvant radiotherapy in Asian women include better treatment compliance among others [29]. Previous studies found ethnic differences in receipt of radiotherapy for both Māori and Pacific women, and were found to be contributory to overall survival differences [5], whereas our study did not demonstrate a disparity for Māori women in the subset of BCS-eligible women. Further research will be beneficial to explain the variations in rates of adjuvant radiotherapy among different ethnic groups.

Age contributed the largest significant determinant to receiving adjuvant radiotherapy after BCS - older women≥70 years were substantially less likely to receive radiotherapy compared to younger women. The referral data indicated that women ≥ 80 years were more likely to not be referred as the clinician deemed it not necessary, and to decline treatment after referral than women of younger age groups. How the variable 'deemed not necessary' is determined and collected (its completeness or representativeness of clinical decision making) is not clear from the dataset. Evidence suggests there are various factors that lead to age differences in receiving radiotherapy, including evidence on lower treatment benefit for older women [36-38], and studies which discuss how information on treatment options is presented, the impact of age on health literacy [39-42], patient's and/or clinician's views or preference related to a type of surgery (or consequent need for radiotherapy or multiple operations), as well as the presence of comorbidities in older women [43]. Presence of comorbidities and less treatment benefit amongst older women may also be related to the lower referral rate for adjuvant radiotherapy.

We found, unexpectedly, that symptomatic women were less likely to receive radiotherapy than those that were screen-detected, particularly as a symptomatic woman may have a higher grade or more advanced stage cancer compared to a screen detected cancer, and therefore optimising local control through adjuvant radiotherapy would be important. On further investigation, this finding appears to reflect the gap reported in the 2016 New Zealand audit, where 93.3% of screen-detected women were referred for radiotherapy compared to 86.9% of symptomatic women [43]. International analyses have reported a range of factors associated with nonreceipt of radiotherapy including socioeconomic status, ethnicity, rurality, and distance from a treatment centre [44–46].

Our study showed a downward trend in rates of receiving adjuvant radiotherapy over 2010–2015, from 96 to 90%. A 2011 US study reported a fluctuating range of 61–70% among early stage breast cancer patients over the past decade [18]. It is expected to see ongoing changes in receipt of adjuvant radiotherapy rates with time as radiotherapy guidelines are continually evolving for breast cancer and evidence from clinical trials enters routine clinical practice [47]. The START trial [12] in 2013 and the FASTFORWARD study [48] in 2020 demonstrated that reduced duration of radiotherapy (3 weeks and 1 week, respectively) by increasing the dose per daily treatment could retain comparable cancer control and cosmetic outcomes in selected patient groups. The EXPERT trial [49], which started recruitment in New Zealand in 2017, is assessing the impact of omitting adjuvant radiotherapy in low risk breast cancers (luminal A and low recurrence score on PAM50 testing) after BCS. The downward trend of adjuvant radiotherapy use likely to represent changes in clinical practice, which may be related to updates in clinical trial-based evidence.

Strengths and limitations

Our research was population-based and included a large cohort of women with breast cancer, covering two-thirds of the whole breast cancer population in New Zealand. Our study's focus on BCS-eligible women facilitated clear interpretation of effect of ethnicity by excluding women with more complex clinical situations, and ethnic differences driven by late stage at presentation. Although a clinically determined variable of 'BCS-eligible' was not available, we used as much relevant information as possible in the analysis; however, some information that may be relevant in this study was unavailable, such as breast density, breast volume, tumour size in relation to breast volume, tumour location, family history/genetic status, patient comorbidities, and contraindications for surgery or adjuvant radiotherapy following BCS. The external validity of this study may be limited given the regional differences in the distribution of ethnicity, age and deprivation score.

Conclusion

In New Zealand women with early breast cancer eligible for BCS, the mastectomy rates were similar in Maori and Pacific women, but significantly higher in Asian women with invasive disease, compared to the Other ethnic group, after adjusting for demographic and clinicopathological factors. Rates of radiotherapy use are high by international standards. The adjuvant radiotherapy rates after BCS were similar in Māori, but substantially lower in Pacific women and higher in Asian women with invasive disease, compared to the Other ethnic group, and lower for symptomatic women. Both of these findings are of concern. Other significant factors affecting treatment choices included age, diagnosis year, mode of detection, and tumour factors such as grade. The radiotherapy referrals revealed a higher rate of non-referral due to it being deemed unnecessary in Asian women, and a higher rate of self-decline after being referred in Pacific women, compared to Other ethnic groups. Further research is required to understand differences by ethnicity in both rates of mastectomy and lower rates of radiotherapy after BCS for Pacific women, and the reasons for non-referral by clinicians.

List of abbreviations

BCS	Breast Conserving Surgery
DCIS	Ductal Carcinoma In Situ
NZBCF	New Zealand Breast Cancer Foundation
NZBCR	New Zealand Breast Cancer Register
NHI	National Health Index
MELAA	Middle Eastern Latin American and African

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12885-023-11248-9.

Supplementary Material 1

Acknowledgements

We would like to acknowledge Dr Charis Brown for the support with coordination of study approvals and data sourcing; Dr Virginia Griffiths for early manuscript development; our advisor – Prof Ross Lawrenson (University of Waikato); and site support and technical advisors – Aroha Haggie (Funding and Health Equity, Counties Manukau district), Dr Sheridan Wilson (Medical Oncologist, Te Toka Tumai Auckland), Dr David Moss (recruitment from Counties Manuaku district), Dr Susan Gerred (recruitment from Waitematā district), Dr Vince Newton (Te Tai Tokerau Northland district), Dr Richard Sullivan (Northern Cancer Network), Dr Ruth Angell (Radiation Oncologist, Te Toka Tumai Auckland district), and Dr Eletha Taylor (Breast Surgeon, Te Toka Tumai Auckland). We also would like to acknowledge the team at the Breast Cancer Registry for this assistance in collating a range of datasets for analysis, and funders HRC and Breast Cancer Foundation (BCF Partnership Grant #18/766).

Authors' contributions

KB: conceptualisation, methodology, supervision, funding acquisition, resources; MG: data curation, methodology, formal analysis, validation; STT: data curation, methodology, formal analysis; PSA: writing original draft, methodology, validation; JME: methodology; CH: methodology; IC: methodology, All authors reviewed and edited the manuscript.

Funding

Health Research Council and the New Zealand Breast Cancer Foundation Partnership Grant #18/766.

Data Availability

The data used and analysed during the current study contain identifiable individual patient information. The data are not publicly available due to the data confidentiality and privacy restrictions but are available from the corresponding author on reasonable request and corresponding approvals. Please contact Health and Disability Ethics Committees at hdecs@health.govt. nz for ethics queries.

Declarations

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

The Te Rēhita Mate Ütaetae, New Zealand Breast Cancer Registry, maintains its own governance and New Zealand Health and Disability Ethics Committee approval, using opt-out consent. The analysis of the registry data for this study was additionally approved by the Health and Disability Ethics Committees (18/ STH/165), and primary site localities at Waitematā (RM#13920). All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Author details

¹Te Whatu Ora Waitematā, Auckland, New Zealand

²Te Whatu Ora Te Toka Tumai Auckland, Auckland, New Zealand ³University of Auckland, 85 Park Road, Grafton, Auckland

1023, New Zealand

⁴Te Whatu Ora MidCentral, Palmerston North, New Zealand

⁵University of Auckland, Waikato Campus, Hamilton, New Zealand ⁶Auckland University of Technology, Auckland, New Zealand

Received: 1 June 2023 / Accepted: 2 August 2023

Published online: 17 August 2023

References

- Health New Zealand. Historical cancer data Te Whatu Ora 2022. https:// www.tewhatuora.govt.nz/our-health-system/data-and-statistics/historicalcancer/ (accessed March 18, 2023).
- Lawrenson R, Seneviratne S, Scott N, Peni T, Brown C, Campbell I. Breast cancer inequities between Māori and non-Māori women in Aotearoa/New Zealand. Eur J Cancer Care (Engl). 2016;25:225–30. https://doi.org/10.1111/ ECC.12473.
- Breast Cancer Foundation NZ. 30,000 voices: informing a better future for breast cancer in Aotearoa New Zealand. Auckland: Breast Cancer Foundation NZ; 2022.
- Teng AM, Atkinson J, Disney G, Wilson N, Sarfati D, McLeod M, et al. Ethnic inequalities in cancer incidence and mortality: Census-linked cohort studies with 87 million years of person-time follow-up. BMC Cancer. 2016;16:1–14. https://doi.org/10.1186/S12885-016-2781-4/FIGURES/5.
- Tin Tin S, Elwood JM, Brown C, Sarfati D, Campbell I, Scott N, et al. Ethnic disparities in breast cancer survival in New Zealand: which factors contribute? BMC Cancer. 2018;18:58. https://doi.org/10.1186/s12885-017-3797-0.
- 6. Ministry of Health NZ. Management of early breast cancer. Wellington: New Zealand Guidelines Group; 2009.
- Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM. Neoadjuvant therapy in early breast Cancer: treatment considerations and common debates in practice. Clin Oncol. 2017;29:642–52. https://doi.org/10.1016/j. clon.2017.06.003.
- van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17:1158–70. https://doi.org/10.1016/ S1470-2045(16)30067-5.
- Christiansen P, Carstensen SL, Ejlertsen B, Kroman N, Offersen B, Bodilsen A, et al. Breast conserving surgery versus mastectomy: overall and relative survival—a population based study by the danish breast Cancer Cooperative Group (DBCG). Acta Oncol (Madr). 2018;57:19–25. https://doi.org/10.1080/02 84186X.2017.1403042.
- Johns N, Dixon JM. Should patients with early breast cancer still be offered the choice of breast conserving surgery or mastectomy? Eur J Surg Oncol (EJSO). 2016;42:1636–41. https://doi.org/10.1016/j.ejso.2016.08.016.
- Abrahimi MS, Elwood M, Lawrenson R, Campbell I, Tin ST. Associated factors and survival outcomes for breast conserving surgery versus mastectomy among New Zealand Women with early-stage breast Cancer. Int J Environ Res Public Health. 2021;18:1–13. https://doi.org/10.3390/JERPH18052738.
- 12. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94.
- Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–16.
- Gollop SJ, Kyle SM, Fancourt MW, Gilkison WTC, Mosquera DA. Why Taranaki women choose to have a mastectomy when suitable for breast conservation treatment. ANZ J Surg. 2009;79:604–9. https://doi. org/10.1111/J.1445-2197.2009.05014.X.

- Seneviratne S, Scott N, Lawrenson R, Campbell I. Ethnic, socio-demographic and socio-economic differences in surgical treatment of breast cancer in N ew Z ealand. ANZ J Surg. 2017;87:E32–9.
- Campbell I, Lao C, Blackmore T, Edwards M, Hayes L, Ng A, et al. Surgical treatment of early stage breast cancer in the Auckland and Waikato regions of New Zealand. ANZ J Surg. 2018;88:1263–8.
- Seneviratne S, Campbell I, Scott N, Coles C, Lawrenson R. Treatment delay for Māori women with breast cancer in New Zealand. Ethn Health. 2015;20:178–93.
- Dragun AE, Huang B, Tucker TC, Spanos WJ. Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer. Cancer. 2011;117:2590–8. https://doi.org/10.1002/CNCR.25821.
- Gabriel G, Barton M, Delaney GP. The effect of travel distance on radiotherapy utilization in NSW and ACT. Radiother Oncol. 2015;117:386–9. https://doi. org/10.1016/J.RADONC.2015.07.031.
- Elwood JM, Marshall RJ, Tin Tin S, Barrios MEP, Harvey VJ. Bias in survival estimates created by a requirement for consent to enter a clinical breast cancer registry 2018. https://doi.org/10.1016/j.canep.2018.12.005.
- Breast Cancer Foundation NZ. Breast conserving surgery 2023. https://www. breastcancerfoundation.org.nz/breast-cancer/treatment-options/surgery/ breast-conserving-surgery (accessed March 18, 2023).
- Ministry of Health NZ. HISO 10001:2017 Ethnicity Data Protocols. Volume 10001. Wellington: Wellington: Ministry of Health; 2017.
- 23. Cormack Donna, McLeod M. Improving and maintaining quality in ethnicity data collections in the health and disability sector. 2010.
- 24. Statistics New Zealand. Datafinder: Rurality 2020.
- Atkinson J, Salmond C, Crampton P, Atkinson J, Salmond C, Crampton P. NZDep2013 index of deprivation. Wellington: Department of Public Health, University of Otago; 2014.
- American Society of Clinical Oncology. Breast Cancer: Stages. CancerNet 2017. https://www.cancer.net/cancer-types/breast-cancer/stages (accessed June 29, 2023).
- Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9–16. https:// doi.org/10.1001/jamasurg.2014.2895.
- Merie R, Shafiq J, Soon PS, Delaney GP. Surgical and radiotherapy patterns of care in the management of breast cancer in NSW and ACT Australia. J Med Imaging Radiat Oncol. 2022;66:442–54. https://doi. org/10.1111/1754-9485.13357.
- 29. Lao C, Lawrenson R, Edwards M, Campbell Chunhuan Lao I. Treatment and survival of asian women diagnosed with breast cancer in New Zealand. n.d.
- Tin ST, Elwood JM, Lawrenson R, Campbell I, Harvey V, Seneviratne S. Differences in breast Cancer survival between Public and Private Care in New Zealand: which factors contribute? PLoS One 2016;11. https://doi.org/10.1371/ JOURNAL.PONE.0153206.
- Ooi CWL, Campbell ID, Kollias J, de Silva P. National breast cancer audit: overview of invasive breast cancer in New Zealand. N Z Med J. 2012;125:8.
- Panchal H, Matros E. Current Trends in Postmastectomy breast Reconstruction. Plast Reconstr Surg. 2017;140. https://doi.org/10.1097/ PRS.000000000003941. :7S-13S.
- Collins IM, Lum C, Versace VL. Influence of socioeconomic factors and distance to radiotherapy on breast-conserving surgery rates for early breast cancer in regional Australia; implications of change. Asia Pac J Clin Oncol. 2018;14:e224–30. https://doi.org/10.1111/ajco.12828.
- 34. Fancellu A. The need to diminish mastectomy rates in patients with breast cancer eligible for breast conservation. Updates Surg. 2019;71:597–8.
- 35. Health Quality & Safety Commission New Zealand. Bula Sautu : a window on quality 2021 : Pacific health in the year of COVID-19 = He mata kounga 2021 : hauora Pasifika i te tau COVID-19. n.d.
- Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon M. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. WwwThelancetCom/Oncology 2015;16. https://doi.org/10.1016/S1470-2045(14)71221-5.
- Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in Women Age 70 years or older with early breast Cancer: long-term Follow-Up of CALGB 9343. J Clin Oncol. 2013;31:2382. https://doi.org/10.1200/JCO.2012.45.2615.
- Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast Cancer. Https://DoiOrg/101056/NEJ-Moa040587 2004;351:971–7. https://doi.org/10.1056/NEJMOA040587.

- Gu J, Groot G, Boden C, Busch A, Holtslander L, Lim H. Review of factors influencing women's choice of Mastectomy Versus breast conserving therapy in early stage breast Cancer: a systematic review. Clin Breast Cancer. 2018;18:e539–54. https://doi.org/10.1016/j.clbc.2017.12.013.
- Recio-Saucedo A, Gerty S, Foster C, Eccles D, Cutress RI. Information requirements of young women with breast cancer treated with mastectomy or breast conserving surgery: a systematic review. The Breast. 2016;25:1–13. https://doi.org/10.1016/j.breast.2015.11.001.
- Hamelinck VC, Bastiaannet E, Pieterse AH, Merkus JWS, Jannink I, den Hoed IDM, et al. A prospective comparison of younger and older patients' preferences for breast-conserving surgery versus mastectomy in early breast cancer. J Geriatr Oncol. 2018;9:170–3. https://doi.org/10.1016/j.jgo.2017.08.011.
- Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in early breast Cancer. N Engl J Med. 2023;388:585–94. https://doi.org/10.1056/NEJMOA2207586/SUPPL_FILE/ NEJMOA2207586_DATA-SHARING.PDF.
- 43. Royal Australasian College of Surgeons for Breast Surgeons of Australia and New Zealand. BreastsurgANZ Quality Audit. BreastScreen Aotearoa Annual Report 2016. Early and locally advanced breast cancer patients diagnosed in New Zealand in 2016. Melbourne: Royal Australasian College of Surgeons; 2018.
- 44. Frisell A, Lagergren J, Halle M, de Boniface J. Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information. Breast Cancer Res Treat. 2020;179:721–9. https://doi.org/10.1007/s10549-019-05496-2.
- 45. Xu Y, Bouchard-Fortier A, Olivotto IA, Cheung WY, Kong S, Kornelsen E, et al. Driving' Rates Down: a Population-Based study of opening New Radiation

Therapy Centers on the use of mastectomy for breast Cancer. Ann Surg Oncol. 2018;25:2994–3003. https://doi.org/10.1245/s10434-018-6619-y.

- Chan J, Griffiths K, Turner A, Tobias J, Clarmont W, Delaney G, et al. Radiation Therapy and Indigenous Peoples in Canada and Australia: Building Paths toward Reconciliation in Cancer Care Delivery. Int J Radiation Oncology*Biology*Physics. 2023. https://doi.org/10.1016/J. UROBP.2022.09.085.
- Shah C, Al-Hilli Z, Vicini F. Advances in breast Cancer Radiotherapy: implications for current and future practice. JCO Oncol Pract. 2021;17:697–706. https://doi.org/10.1200/op.21.00635.
- Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613–26. https://doi.org/10.1016/S0140-6736(20)30932-6.
- 49. Chua BH, Gray K, Krishnasamy M, Regan M, Zdenkowski N, Loi S, et al. Examining personalized radiation therapy (EXPERT): A randomised phase III trial of adjuvant radiotherapy vs observation in patients with molecularly characterized luminal A breast cancer. Cancer Res, vol. 79, AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA ...; 2019.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.